PTC Therapeutics/$PTCT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About PTC Therapeutics
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
- Ticker
- $PTCT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 991
- Headquarters
- Warren, United States
- Website
- www.ptcbio.com
PTC Therapeutics Metrics
BasicAdvanced
$5.1B
-
-$1.28
0.49
-
Price and volume
Market cap
$5.1B
Beta
0.49
52-week high
$90.87
52-week low
$58.80
Average daily volume
1.1M
Financial strength
Current ratio
3.27
Quick ratio
3.049
Long term debt to equity
-13.641
Total debt to equity
-15.384
Interest coverage (TTM)
1.25%
Profitability
EBITDA (TTM)
309.559
Gross margin (TTM)
55.18%
Net profit margin (TTM)
-9.17%
Operating margin (TTM)
21.51%
Effective tax rate (TTM)
-24.54%
Revenue per employee (TTM)
$1,170,000
Management effectiveness
Return on assets (TTM)
5.31%
Return on equity (TTM)
61.08%
Valuation
Price to revenue (TTM)
4.369
Price to book
-26.64
Price to tangible book (TTM)
-7.1
Price to free cash flow (TTM)
-122.173
Free cash flow yield (TTM)
-0.82%
Free cash flow per share (TTM)
-0.499
Growth
Revenue change (TTM)
-35.05%
Earnings per share change (TTM)
-114.32%
3-year revenue growth (CAGR)
13.13%
10-year revenue growth (CAGR)
32.32%
3-year earnings per share growth (CAGR)
-47.13%
10-year earnings per share growth (CAGR)
-12.55%
What the Analysts think about PTC Therapeutics
Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.
Analyst projections of the future price of PTC Therapeutics stock.
Bulls say / Bears say
Sephience is scaling quickly: third-quarter sales reached $182 million, up 20% from the prior quarter, and PTC raised its 2026 product revenue outlook to $960–990 million. Management also expects cash flow breakeven this year. (PTC Therapeutics)
Votoplam’s 24-month extension results showed dose-dependent slowing of disease progression, including 52% at the higher dose in Stage 2 patients versus an external natural-history cohort. Novartis has begun a global Phase 3 trial, which also triggered a $50 million milestone payment to PTC. (PTC Therapeutics, PTC Therapeutics)
ST-920 adds a potential Fabry disease launch to the pipeline: the Phase 1/2 study showed a positive average eGFR slope at 52 weeks, and PTC expects to complete its FDA application in Q4 2026, with a possible launch in 2027. (PTC Therapeutics)
PTC’s older Duchenne franchise is under pressure: Translarna lost its EU authorisation and PTC withdrew its US application after FDA feedback, while Emflaza sales fell to $25.1 million from $35.2 million as generics gained ground. (SEC)
Vatiquinone faces a significant regulatory hurdle: the FDA said the evidence did not establish efficacy and asked for another adequate, controlled study. PTC’s new study uses an open-label treatment arm with a matched natural-history comparison, so approval remains uncertain. (SEC)
Strong sales have not yet produced steady earnings: PTC reported a $51.7 million third-quarter net loss and $45.9 million in net interest expense, with $536 million of debt and a $2.3 billion liability linked to sold future royalties. These financing costs may limit the benefit of revenue growth to shareholders. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
PTC Therapeutics Financial Performance
Revenues and expenses
PTC Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
PTC Therapeutics News
AllArticlesVideos
Funds containing PTC Therapeutics
Fund name | Fund size | $PTCT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.6B | 0.52% |
iShares Healthcare Innovation£DRDR | $1.6B | 0.52% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.52% |
iShares Ageing Population$AGED | $887M | 0.42% |
iShares Ageing Population£AGES | $887M | 0.42% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

